Senseonics Holdings, Inc. (SENS)
Senseonics: Eversense 365 Adoption Has To Earn The Valuation
Senseonics is rated Hold due to positive sales growth, margin improvement, and product differentiation, but with significant adoption and funding risks. SENS's Eversense 365 offers unique implantable CGM technology, but recurring revenue depends on repeat implantations and overcoming barriers like prescriber adoption and insurance approvals. Q2 2026 saw 117.8% sales growth and gross margin improvement to 59.1%, but high SG&A expenses, ongoing dilution, and negative free cash flow persist.
Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights
Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.
Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript
Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript
Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.4 per share a year ago.
Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?
Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership
SENS partners with Welldoc on a next-gen Eversense 365 app, adding Apple Health/Google Health Connect integration ahead of the U.S. launch.
Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
Senseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlights
Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue outlook after reporting first-quarter growth tied to adoption of its Eversense 365 continuous glucose monitoring system and the integration of its U.S. commercial organization.
Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
Senseonics Holdings (SENS) Reports Q1 Loss, Beats Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.4 per share a year ago.
SENS Launches Eversense 365, World's Only One-Year CGM in Europe
Senseonics launches Eversense 365 in Europe, debuting the first year-long CGM system as it expands into key markets and targets millions of new patients.
Senseonics Reports Strong One-Year Real-World Data for Eversense 365
SENS highlights strong one-year real-world data for Eversense 365, reinforcing adherence, glucose control and long-term adoption potential.
